<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00491491</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-07-4466-AN-CTIL</org_study_id>
    <nct_id>NCT00491491</nct_id>
  </id_info>
  <brief_title>Zevalin-beam for Aggressive Lymphoma</brief_title>
  <official_title>SPINOZA / שפינוזה. Study With Preparatory INduction Of Zevalin in Aggressive Lymphoma. A Randomized Phase 3 Study of BEAM Versus 90Yttrium Ibritumomab Tiuxetan (Zevalin) / BEAM in Patients Requiring Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Relapsed Diffuse Large B-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Göttingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study hypothesis is that the addition of zevalin radioimmunotherapy to the conditioning
      regimen given prior to BEAM high-dose chemotherapy and autologous stem cell transplantation
      in patients with aggressive lymphoma will reduced disease recurrence rate and improve overall
      and disease-free survival.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>2 years after transplantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>2 years after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical response</measure>
    <time_frame>100 days after transplantation</time_frame>
    <description>complete response (CR) and partial response (PR) proportion at day 100,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hematopoietic recovery</measure>
    <time_frame>100 days after transplantation</time_frame>
    <description>time to hematopoietic recovery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxicity</measure>
    <time_frame>100 days after transplantation</time_frame>
    <description>incidence of infection, grade III-IV toxicities, treatment-related mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>secondary malignancies</measure>
    <time_frame>5 years after transplantation</time_frame>
    <description>incidence of myelodysplastic syndrome (MDS), and secondary acute myelogenous leukemia (AML).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>Z-BEAM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ibritumomab tiuxetan (zevalin) BEAM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard BEAM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard BEAM chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ibritumomab tiuxetan</intervention_name>
    <description>0.4 mCi/kg</description>
    <arm_group_label>Z-BEAM</arm_group_label>
    <other_name>zevalin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>BEAM chemotherapy and autologous stem-cell transplantation</intervention_name>
    <arm_group_label>Z-BEAM</arm_group_label>
    <arm_group_label>standard BEAM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with CD20 positive diffuse large B-cell lymphoma as confirmed by a
             pathological biopsy report.

          2. Patients who are candidates for autologous stem-cell transplantation due to primary
             refractory or first relapse of disease.

          3. Patients must have chemo-sensitive disease achieving at least partial response (Cheson
             2007 criteria) to last chemotherapy.

          4. Age ≥ 18 years and age ≤ 70

          5. Patients with adequate autologous stem cell collection for transplantation (target ≥
             2.5 x 106 CD34+ cells/kg).

          6. Patients must sign written informed consent.

          7. Adequate birth control in fertile patients.

          8. All prior chemotherapy completed at least three weeks before study treatment.

          9. Marrow involvement less than 25% at transplantation, no limitation on blood counts
             (low platelet count allowed).

         10. Negative HIV antibody.

        Exclusion Criteria:

          1. 1. Chemo-refractory disease as determined by less than partial response (Cheson 2007
             Criteria) to last chemotherapy.

          2. Two or more relapses after initial response to induction chemotherapy.

          3. High-grade transformation from earlier diagnosis of low-grade lymphoma. Patients with
             &quot;De Novo&quot; Transformed DLBCL, defined as DLBCL only on lymph node biopsy and a
             discordant marrow with para-trabecular small cells at first diagnosis of lymphoma, are
             eligible if adherent all other selection criteria.

          4. Bilirubin &gt; 3.0 mg/dl, transaminases &gt; 3 times upper normal limit.

          5. Creatinine &gt; 2.0 mg/dl.

          6. ECOG Performance status &gt; 2.

          7. Uncontrolled infection.

          8. Pregnancy or lactation.

          9. Abnormal lung diffusion capacity (DLCO &lt; 40% predicted).

         10. Severe cardiovascular disease; New York Heart Association (NYHA) Functional
             Classification ≥2.

         11. Active CNS disease involvement.

         12. Presence of any other malignancy or history of prior malignancy within 5 years of
             study entry. Within 5 years, patients treated for Stage I or II cancers are eligible
             provided they have a life expectancy &gt; 5 years in relation to this prior malignance.
             The 5-year exclusion rule does not apply to-non melanoma skin tumors and in situ
             cervical cancer.

         13. Pleural effusion or ascites &gt; 1 liter.

         14. Known hypersensitivity to rituximab.

         15. Psychiatric conditions/disease that impair the ability to give informed consent or to
             adequately co-operate.

         16. Prior radioimmunotherapy.

         17. Prior autologous or allogeneic HSCT.

         18. Active evidence of Hepatitis B or C infection; Hepatitis B surface antigen positive.

         19. Patients who have had prior radiation to the lung will be excluded from the study,
             although mediastinal irradiation will be permitted if minimal lung is in the treatment
             volume.

         20. Patients who have received &gt;500cGy radiation to the kidneys will be excluded from the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Avichai Shimoni, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Chaim Sheba Medical Center, Tel Hashomer, Israel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amrita Krishnan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>City of Hope National Medical Center, Duarte, CA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georg-August Universität</name>
      <address>
        <city>Göttingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VU Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Israel</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2007</study_first_submitted>
  <study_first_submitted_qc>June 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2007</study_first_posted>
  <last_update_submitted>December 1, 2015</last_update_submitted>
  <last_update_submitted_qc>December 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sheba Medical Center</investigator_affiliation>
    <investigator_full_name>Dr. Avichai Shimoni MD</investigator_full_name>
    <investigator_title>Dr. Avichai Shimoni</investigator_title>
  </responsible_party>
  <keyword>non-Hodgkin's lymphoma</keyword>
  <keyword>autologous stem cell transplantation</keyword>
  <keyword>radioimmunotherapy</keyword>
  <keyword>zevalin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

